Hailen Mak, MD
Allergy · Palo Alto
- Medicare standing
- 2 flags on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
- California licence: Delinquent
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Mak’s office at (650) 322-3847 to ask if they take your plan before you enroll.
California Medical Board record
Licence G29821 · Delinquent
Licence status: Delinquent · since 1975 · expires 2024-06-30 · New York University School of Medicine.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 32 Part D prescriptions in 2019. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2019 | 32 | None | 0% (0) | 53% | $9,297 |
| 2018 | 45 | 17 | 0% (0) | 40% | $12,193 |
| 2017 | 43 | 16 | 0% (0) | 67% | $12,470 |
| 2016 | 54 | 12 | 0% (0) | 56% | $9,266 |
| 2015 | 54 | 17 | 0% (0) | 61% | $10,686 |
| 2014 | 43 | None | 0% (0) | 72% | $5,604 |
| 2013 | 34 | None | 0% (0) | 68% | $5,315 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2018: 1 drug
| Montelukast | 18 | $396 | $22 |
2017: 1 drug
| Advair Diskus | 16 | $4,631 | $289 |
2016: 1 drug
| Advair Diskus | 11 | $3,364 | $306 |
2014: 1 drug
| Ventolin Hfa | 12 | $543 | $45 |
Money from drug and device companies
$206 in 2021
| 2021 | 1 | 4 | None | $206 |
| 2020 | 2 | 3 | None | $166 |
| 2019 | 3 | 3 | None | $221 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| ALK-Abello | None | $206 | 4 payments
|
See all 4 published payments
| ALK-Abello | Meals · 2021-08-30 | None | $44 |
| ALK-Abello | Meals · 2021-05-17 | None | $36 |
| ALK-Abello | Meals · 2021-03-04 | None | $75 |
| ALK-Abello | Meals · 2021-02-28 | None | $50 |
See earlier years (2020, 2019)
2020: $166
| ALK-Abello | Odactra | $149 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | None | $17 | 1 payment
|
2019: $221
| OptiNose US | Xhance | $122 | 1 payment
|
| CSL Behring | Hizentra | $75 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Symbicort | $25 | 1 payment
|
Professional record
- NPI
- 1225083868
- Licence
- CA G29821California G29821: Delinquent · expires 2024-06-30
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207KA0200X (207KA0200X)
- Mailing address
- 1510 Oakcreek Dr, #405, Palo Alto, CA, 94304
- NPI first listed
- 2006-05-23
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.